Aileron Therapeutics Stock Forecast, Price & News

Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

Is Aileron Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aileron Therapeutics stock.
View analyst ratings for Aileron Therapeutics or view top-rated stocks.

How has Aileron Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Aileron Therapeutics' stock was trading at $0.4031 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALRN stock has increased by 43.9% and is now trading at $0.5799.
View which stocks have been most impacted by COVID-19.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 890,400 shares, a decline of 26.4% from the October 31st total of 1,210,000 shares. Based on an average daily trading volume, of 587,200 shares, the short-interest ratio is currently 1.5 days. Approximately 1.4% of the shares of the stock are sold short.
View Aileron Therapeutics' Short Interest.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Aileron Therapeutics.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) released its quarterly earnings data on Friday, November, 12th. The company reported ($0.07) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.07).
View Aileron Therapeutics' earnings history.

What price target have analysts set for ALRN?

2 equities research analysts have issued 1-year price objectives for Aileron Therapeutics' stock. Their forecasts range from $2.00 to $5.00. On average, they anticipate Aileron Therapeutics' share price to reach $3.50 in the next year. This suggests a possible upside of 503.6% from the stock's current price.
View analysts' price targets for Aileron Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the following people:

• Manuel C. Alves Aivado, President, Chief Executive Officer & Director
• Richard J. Wanstall, Chief Financial Officer & Treasurer
• Vojislav Vukovic, Chief Medical Officer & Senior Vice President
• Dora Ferrari, VP-Clinical Development & Program Management
• David Allen Annis, Senior Vice President-Research

Who are some of Aileron Therapeutics' key competitors?

Some companies that are related to Aileron Therapeutics include CM Life Sciences III (CMLT), Vincerx Pharma (VINC), DURECT (DRRX), Impel NeuroPharma (IMPL), Wave Life Sciences (WVE), Avalo Therapeutics (AVTX), Immunome (IMNM), Paratek Pharmaceuticals (PRTK), AVEO Pharmaceuticals (AVEO), TherapeuticsMD (TXMD), Aquestive Therapeutics (AQST), Ardelyx (ARDX), Sensei Biotherapeutics (SNSE), Frequency Therapeutics (FREQ) and Terns Pharmaceuticals (TERN).
View all of ALRN's competitors.

What other stocks do shareholders of Aileron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV).

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.91%), Renaissance Technologies LLC (0.81%), Game Plan Financial Advisors LLC (0.14%), Keebeck Wealth Management LLC (0.08%), Morgan Jess S & Co. Inc. (0.08%) and JFS Wealth Advisors LLC (0.04%). Company insiders that own Aileron Therapeutics stock include Muneer A Satter, Reinhard J Ambros and Rickenbach Josef H Von.
View institutional ownership trends for Aileron Therapeutics.

Which major investors are selling Aileron Therapeutics stock?

ALRN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Keebeck Wealth Management LLC.
View insider buying and selling activity for Aileron Therapeutics or view top insider-selling stocks.

Which major investors are buying Aileron Therapeutics stock?

ALRN stock was acquired by a variety of institutional investors in the last quarter, including Morgan Jess S & Co. Inc., Geode Capital Management LLC, JFS Wealth Advisors LLC, Game Plan Financial Advisors LLC, and Barclays PLC. Company insiders that have bought Aileron Therapeutics stock in the last two years include Muneer A Satter, Reinhard J Ambros, and Rickenbach Josef H Von.
View insider buying and selling activity for Aileron Therapeutics or or view top insider-buying stocks.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $0.58.

How much money does Aileron Therapeutics make?

Aileron Therapeutics has a market capitalization of $52.52 million. The company earns $-21.16 million in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does Aileron Therapeutics have?

Aileron Therapeutics employs 8 workers across the globe.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is www.aileronrx.com.

Where are Aileron Therapeutics' headquarters?

Aileron Therapeutics is headquartered at 490 Arsenal Way, Watertown MA, 02472.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at (617) 995-0900 or via email at [email protected].